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Biopenukaran Isoflavon di dalam Susu Soya-Sinbiotik dengan Menggunakan 
Rawatan Fizikal (Ultrasonikasi, Elektroporasi dan Ultralembayung) pada 
Laktobasili dan Bifidobakteria  
 
ABSTRAK 
 
Lima belas laktobasili dan bifidobakteria disaring dengan pertumbuhan di 
dalam susu soya. L. casei FTDC 2113, L. acidophilus FTDC 8033, L. acidophilus 
BT 4356, L. casei  BT 1268, Bifidobacterium sp. FTDC 8943 dan B. longum FTDC 
8643 menunjukkan kebolehhidupan yang lebih tinggi di dalam susu soya dan justeru 
itu dipilih untuk analisis-analisis berikutnya yang melibatkan penambahan dengan 
prebiotik seperti fruktooligosakarida (FOS), inulin, manitol, maltodekstrin dan 
pectin. Laktobasili dan bifidobakteria yang dipilih menunjukkan kebolehhidupan 
melebihi 7 Log10 CFU/mL selepas fermentasi selama 24 j pada suhu 37 
o
C dan  
meningkat apabila ditambah dengan maltodekstrin, manitol dan FOS.  
Penambahan prebiotik juga meningkatkan aktiviti rencatan-ACE. Di samping 
itu, penambahan prebiotik seperti pektin juga meningkatkan aktiviti β-glukosidase 
ekstrasel. Aktiviti β-glukosidase intrasel juga dipertingkatkan apabila susu soya 
ditambah dengan pektin dan manitol. Hal ini kemudiannya disertai dengan 
peningkatan biopenukaran glukosida kepada aglikon di dalam susu soya prebiotik. 
Antara prebiotik tersebut, manitol menunjukkan kesan yang lebih ketara dalam 
menggalakkan penghasilan aglikon bioaktif di dalam susu soya. 
Maka, susu soya-manitol digunakan dalam kajian-kajian seterusnya yang 
melibatkan ultrasonik (20-100 W; 1-3 min), sinaran ultralembayung (UVA-UVC, 30-
90 J/m
2
) dan elektroporasi (2.5-7.5 kV/cm; 3-4 ms). Rawatan-rawatan fizikal ini 
mendorong kebolehhidupan laktobasili dan bifidobakteria di dalam susu soya-
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manitol. Hal ini disebabkan oleh peningkatan kebolehtelapan membran yang 
berpunca daripada pengoksidaan lipid dan perubahan pada membran dwilapisan 
fosfolipid selepas rawatan-rawatan fizikal. Rawatan-rawatan tersebut juga 
menggalakkan aktiviti-aktiviti β-glukosidase intrasel dan ekstrasel laktobasili dan 
bifidobakteria, dan seterusnya meningkatkan biopenukaran glukosida kepada aglikon 
di dalam susu soya-manitol. Elektroporasi pada 7.5 kV/cm untuk 3.5 ms 
menunjukkan kesan yang lebih ketara di mana kepekatan aglikon meningkat 
sebanyak 78.2% berbanding dengan kawalan dan hal ini jelas diperhatikan di dalam 
susu soya-manitol yang difermentasikan oleh B. longum FTDC 8643. Ultrasonik (60 
W; 3 min) dan sinaran ultralembayung (UVB; 90 J/m
2
) juga berkesan dalam 
meningkatkan kepekatan aglikon dan paling jelas ditunjukkan di dalam susu soya-
manitol yang difermentasikan oleh L. casei FTDC 2113 (43.1-46.7% lebih tinggi 
berbanding dengan kawalan). Rawatan-rawatan fizikal dan Lactobacillus and 
Bifidobacterium tersebut kemudian dipilih untuk analisis melibatkan warisan oleh 
subkultur berikutnya. Peningkatan kebolehhidupan dan biopenukaran glukosida 
kepada aglikon dan peningkatan ciri-ciri probiotik semasa rawatan-rawatan fizikal 
hanya terdapat dalam sel-sel induk tanpa diwarisi oleh subkultur berikutnya 
(subkultur pertama, kedua dan ketiga). Walaupun hanya untuk sementara, kajian ini 
jelas menunjukkan bahawa rawatan-rawatan fizikal tersebut sememangnya 
bermanfaat untuk menggalakkan potensi probiotik dan bioaktif Lactobacillus dan 
Bifidobacterium di dalam susu soya-manitol, untuk penghasilan susu soya sinbiotik 
berfungsi yang mempunyai bioaktiviti yang tinggi. 
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Bioconversion of Isoflavones in Synbiotic-Soymilk using Physical Treatments 
(Ultrasonication, Electroporation and Ultraviolet) on Lactobacilli and 
Bifidobacteria 
 
ABSTRACT 
 
Fifteen strains of lactobacilli and bifidobacteria were screened for growth in 
soymilk. L. casei FTDC 2113, L. acidophilus FTDC 8033, L. acidophilus BT 4356, 
L. casei BT 1268, Bifidobacterium sp. FTDC 8943 and B. longum FTDC 8643 
exhibited higher (P<0.05) viability and were thus selected for subsequent analyses 
involving prebiotics such as fructooligosaccharides (FOS), inulin, mannitol, 
maltodextrin and pectin. All selected strains showed viability exceeding 7 Log10 
CFU/mL upon fermentation in soymilk at 37 
o
C for 24 h and was higher upon 
supplementation with maltodextrin, mannitol and FOS.  
Supplementation of prebiotics also increased angiotensin I-converting 
enzyme (ACE)-inhibitory activity. In addition, supplementation with prebiotics such 
as pectin also enhanced the extracellular β-glucosidase. The intracellular β-
glucosidase activity was enhanced upon supplementation with pectin and mannitol. 
This led to a higher bioconversion of glucosides to aglycones in soymilk 
supplemented with these prebiotics. Among the prebiotics, mannitol showed a more 
prominent effect on promoting the production of bioactive aglycones in soymilk.  
Therefore, mannitol-soymilk was used for subsequent evaluations upon 
application of ultrasound (20-100 W; 1-3 min), UV radiation (UVA-UVC, 30-90 
J/m
2
) and electroporation (2.5-7.5 kV/cm; 3-4 ms). These physical treatments 
significantly promoted the viability of lactobacilli and bifidobacteria in mannitol-
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soymilk mainly due to enhanced membrane permeability of cells upon treatments. 
Such changes were attributed to lipid peroxidation and alteration on membrane 
phospholipids bilayer. Such physical treatments also significantly promoted the 
intracellular and extracellular β-glucosidase activities of lactobacilli and 
bifidobacteria, and subsequently enhanced the bioconversion of glucosides to 
aglycones in mannitol-soymilk (P<0.05). Electroporation at 7.5 kV/cm for 3.5 ms 
showed a more prominent effect where concentrations of aglycones was increased by 
78.2% compared to the control and this was clearly observed in mannitol-soymilk 
fermented by B. longum FTDC 8643. Ultrasound (60 W; 3 min) and UV radiation 
(UVB; 90 J/m
2
) also effectively promoted the concentrations of aglycones and was 
most prevalent in mannitol-soymilk fermented by L. casei FTDC 2113 (43.1-46.7% 
higher compared to that of the control). These treatments and strains were then 
selected for analyses involving inheritance potential by subsequent subcultures. The 
increase in viability, bioconversion of isoflavones and enhancement of probiotic 
properties upon physical treatments were only prevalent in the parent cells (P<0.05), 
without inheritance by subsequent subcultures (first, second and third subculture) of 
treated cells. Although temporary, the results strongly illustrated that physical 
treatments may be beneficial for promoting the probiotic and bioactive potentials of 
Lactobacillus and Bifidobacterium in mannitol-soymilk, for the development of 
functional synbiotic-soymilk with enhanced bioactivity.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Background 
Lactobacilli and bifidobacteria are known as the most common type of 
bacteria exhibiting probiotic properties. Probiotics are defined as ‗live 
microorganisms that when administered in adequate amounts confer health benefits 
on the host‘ (Guarner et al., 2005). These bacteria are proclaimed to impart health 
beneficial effects such as alleviation of immune system, modulation of 
gastrointestinal microbial balance and prevention of gastrointestinal infection (Liong, 
2007). Due to their potential health benefits, there are growing interest to incorporate 
it into food preparation to produce healthy functional products.  
Soybean (Glycine max) is well known as an inexpensive source of protein 
and carbohydrate for human consumption. It does not contain cholesterol and lactose 
and thus suitable for lactose intolerance consumer (Wang et al., 2003). Past 
epidemiological studies and clinical trials have shown promising evidence on the 
importance of soy in prevention of postmenopausal symptoms, cardiovascular 
disease, bone health problems, and breast, prostate and colon cancers (Setchell and 
Cassidy, 1999). Despite the attractive nutritional attribute of soy, consumption of soy 
has been limited due to the undesirable beany flavour and the presence of 
oligosaccharides (stachyose and raffinose) that often lead to flatulence. 
Oligosaccharides could be hydrolyzed by α-galactosidase, an enzyme which is 
usually deficient in the human intestinal tract. Lactobacilli and bifidobacteria have 
been reported to possess varying levels of α-galactosidase. Fung et al. (2008a) 
demonstrated that L. acidophillus could hydrolyze the oligosaccharides in soy whey, 
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while Liong et al. (2009) reported that the incorporation of Lactobacillus with α-
galactosidse activity significantly increased the hydrolysis of soybean 
oligosaccharides and subsequently reduced such antinutritive property in soy cream 
cheese.  
In addition, soy contains reasonable amounts of proteins which when 
metabolized by Lactobacillus and Bifidobacterium, yield bioactive peptides known 
to confer health benefits (Liong et al., 2009). These bacteria were found to possess 
proteolytic activity which could cleave the soy protein into various amino acid and 
peptides. Some of the peptides produced by Lactobacillus and Bifidobacterium are 
found to be bioactive and could impart antihypertensive effect (Ng et al., 2008).  
Soybeans also contain appreciable amounts of isoflavones which are 
responsible for the vast beneficial effects of soy. Isoflavones are nonsteroidal 
phytoestrogenic and antioxidative polyphenolic molecules with the potential to 
protect against hormone-dependent diseases due to its partial agonist and antagonist 
estrogens effects (Kano et al., 2006). Izumi et al. (2000) demonstrated that aglycones 
are absorbed faster and in higher amount than glucosides in human. However, 
approximately 80% - 95% of isoflavones in unfermented soybean exist as glucosides 
which are less bioactive and nonbioavailable. β-Glucosidase producing lactobacilli 
and bifidobacteria has been reported to biotransform isoflavones glucosides to 
biologically potent aglycones (Tsangalis et al., 2002).  
Prebiotics are food ingredients that are neither hydrolyzed nor absorbed in the 
upper part of the gastrointestinal tract, and is selectively used as a substrate for 
beneficial bacteria in the colon (Liong and Shah, 2006). Oligosaccharides are the 
most common and widely researched prebiotics, especially fructooligosaccharides 
(FOS) and inulin. The viability and enzyme activity of Bifidobacterium was 
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reportedly induced by prebiotics (Rastall and Maitin, 2002). Therefore, interest has 
been raised to incorporate prebiotics into probiotic preparations which is term as 
synbiotics. Synbiotics are defined as ‗a mixture of probiotics and prebiotics that 
beneficially affects the host by improving the survival and implantation of live 
microbial dietary supplements in the gastrointestinal tract and thus improving host 
welfare‘ (Tuohy et al., 2003).  
Supplementation of skim milk powder and lactulose in Lactobacillus-
fermented soymilk has been demonstrated to increase the production of β-
glucosidase enzyme and subsequently enhanced the bioconversion of isoflavones in 
soy (Pham and Shah, 2007; Pham and Shah, 2008a). However, up to date, little 
information is available on the effect of prebiotics on the bioconversion of 
isoflavones by lactobacilli and bifidobacteria in soy medium. To our knowledge, 
there have been no studies evaluating the effects of prebiotics such as pectin, 
mannitol and maltodextrin on the growth characteristic, antihypertensive properties 
and bioconversion of isoflavones in soy-products fermented by lactobacilli and 
bifidobacteria.  
It is important to note that, the efficient bioconversion of isoflavones in soy 
products by lactobacilli and bifidobacteria is strongly influenced by permeability of 
cellular membrane. Generally, cellular membrane acts as a semipermeable barrier for 
transport of substance into and out of cells (Tryfona and Bustard, 2008). Selective 
permeability of the cellular membrane may prevent an efficient transport of 
isoflavones and β-glucosidase enzyme across the membrane. This subsequently 
impedes the bioconversion of isoflavones in soy products by cells. Furthermore, the 
cellular membrane could also limit the release of transformed bioactive products 
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extracellularly. Therefore, permeabilization of cell membrane is essential to 
overcome the limitation of material transfer across the cellular membrane. 
Physical treatments such as electroporation, ultrasound and ultraviolet radiation 
could efficiently permeabilize cellular membrane and promote the transport of 
substances across the cellular membrane without causing cell death. Considering the 
enhanced permeabilization, these physical treatments have demonstrated to impart 
various biotechnological applications. Loghavi et al. (2007) previously reported that 
electroporation (1V/cm, 60Hz, for 40h) promoted the production of bacteriocins 
(lacidin A) by L. acidophilus without causing cell death. In another study, Ohshima 
et al. (1995) demonstrated that application of electroporation on brewers‘ yeast, 
Saccharomyces cerevisiae increased the extracellular activities of invertase and 
alcohol dehydrogenase without destruction of cells. All these were attributed to the 
temporary pores created by the external electric field which increased the diffusive 
permeability of bioactive components and enzymes across the cellular membrane.  
Ultrasound treatment has also been demonstrated to enhance biotechnological 
potential where Wu et al. (2000) reported that ultrasound treatment stimulated the 
acid production by starter culture and reduced the fermentation time in yogurt 
without inactivating the cultures. In addition, Wang et al. (1995) demonstrated that 
ultrasound increased the viable cell counts and β-galactosidase activity of 
Lactobacillus and Bifidobacterium in milk which led to subsequent increased of 
lactose hydrolysis in milk. In another study, ultrasound followed by static incubation 
was reported to increase the viable cell counts of Brevibacterium sp. and production 
of cholesterol oxidase (Yang et al., 2010). These were due to the reversible alteration 
of membrane properties upon ultrasound treatments on the cells. 
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In addition, UV radiation has also shown promising evidences in promoting 
permeabilization and bioprocesses. Despite conventionally used for sterilization 
purpose, UV radiation, under appropriate dose would only caused sublethal injuries 
where the cells exhibited a longer lag phase prior to resuming viability (Berney et al., 
2007). This was in agreement with the study of Kramer and Ames (1987) who 
reported that S. typhimurium recovered and resumed viability after exposure to a low 
intensity of UV radiation. UV radiation (253.7 nm; 4.7 W/m
2
) has also been reported 
to increase permeability of ions across the membrane of Chara corallina (Doughty 
and Hope, 1973), attributed to the reversible alteration of membrane properties. In 
another study, Shimizu and Sekiguchi (1979) reported that UV radiation effectively 
permeabilized E. coli cells and thus enabled the transport of macromolecules such as 
enzyme across the membrane while retaining the colony forming ability.  
Thus, we hypothesized that the transient elimination of permeability barrier by 
physical treatments could enhance growth properties and yield of bioactive 
compound by whole cells. However, up to date, no attempt has been made to utilize 
such treatments to improve the production of bioactive isoflavones aglycones by 
lactobacilli and bifidobacteria. In addition, the effects of physical treatments on 
bioactivities of the offspring cells are also not well understood with the currently 
available limited information. Therefore, more studies are needed to better 
understand the effects of physical treatments on the bioactive potentials in 
subsequent offspring cells generated after few growth cycles (first, second and third 
subculture of cells). 
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1.2 Aim and Objectives for Research 
The aim of this study is to evaluate the effects of prebiotics on the growth 
characteristics of lactobacilli and bifidobacteria and bioconversion of isoflavones in 
soymilk, and the effects of subsequent physical treatments on the bioactivity of 
synbiotic-soymilk.  
 
Specific and measurable objectives  
1. To screen and select strains of lactobacilli and bifidobacteria based on 
viability in soymilk. 
2. To screen and evaluate the effects of prebiotics on the growth properties and 
bioactive potential of lactobacilli and bifidobacteria in soymilk.   
3. To evaluate the effects of physical treatments on viability and membrane 
properties of lactobacilli and bifidobacteria in synbiotic-soymilk. 
4. To assess the effects of physical treatments on bioconversion of isoflavones 
by lactobacilli and bifidobacteria in the synbiotic-soymilk.   
5. To determine possible carry-over effects of physical treatments on viability 
and bioactivity in subsequent subcultures of cell.   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Probiotics 
Probiotics are defined as ‗live microorganism which when added to foods 
help restore gut microflora of the host and subsequently confer health beneficial 
properties‘ (Desai et al., 2004). The beneficial health promoting effects of probiotics 
include immune modulation, antihypertensive, anticarcinogenic, reduction of serum 
cholesterol and prevention of gastrointestinal infection. 
 
2.1.1 Lactobacillus 
Lactobacilli are straight Gram-positive, non-motile and non-spore forming 
organisms that commonly form chains, with optimum pH of 4.5 - 6.0. Owing to their 
microaerophillic nature, they can tolerate oxygen or live anaerobically. Lactobacilli 
have complex nutritional requirements for carbohydrates, amino acids, peptides, fatty 
acids, nucleic acid derivatives, vitamins and minerals. Lactobacillus could be either 
homofermentative or heterofermentative where carbohydrates are used as carbon and 
energy source. These sugars or oligosaccharides are transported into the cell by the 
phosphotransferase system or the permease system (Konig and Frohlich, 2008). 
Lactobacillus can be characterised based on their physiological properties to three 
groups which include obligate homofermentation, facultative heterofermentation and 
obligate heterofermentation. L. acidophilus and L. bulgaricus are mainly obligate 
homofermentaters, L. casei are characterised as facultative heterofermentative while 
L. fermentum are obligate heterofermentative. Homofermentation ferment glucose 
via the Embden-Meyerhof-Parnas pathway converting 1 mol glucose to 2 mol lactic 
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acid while heterofermentation proceed via the hexosemonophosphate pathway 
resulting in 1 mol each of lactic acid, ethanol/acetate and CO2. 
 
2.1.2 Bifidobacterium 
Bifidobacteria are Gram-positive, saccharolytic anaerobes which occur 
ubiquitously in the human gut, with optimum pH of 6.0 and 7.0 and optimum 
temperature of 37 
o
C-41 ºC. Carbohydrates are degraded exclusively and 
characteristically by the fructose-6-phosphate shunt. In pure glucose medium, 
bifidobacteria produce acetic and lactic acid in a molar ratio of 3:2. They are also 
capable of utilizing a variety of carbohydrate as carbon sources because of their 
ability to produce several intracellular and extracellular depolymerizing enzymes 
(Amaretti et al., 2006). Complex carbohydrate such as oligosaccharides and 
polysaccharides were initially depolymerized to their respective monomeric 
constituents prior to incorporation into the fructose-6-phosphate shunt and fermented 
to lactic and acetic acids.  
 
2.1.3 Health Promoting Benefits of Probiotics 
Conventionally, probiotics have been demonstrated to promote 
gastrointestinal health by modulating gut microbial balance. In recent years, 
application of probiotics has been extended beyond gastrointestinal health to include 
prevention of killer disease such as cancer. In vivo studies have shown promising 
evidence that there is a strong correlation between probiotics and reduced risks of 
colon cancer induced by mutagens such as heterocyclic amines. Tavan et al. (2002) 
conducted a randomised study involving 60 weanling male rats which were induced 
with 250 mg of mutagens/carcinogens. These mutagens induced rats were randomly 
assigned to four groups each fed with water, non-fermented milk, B.
 
animalis (5.4 ± 
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1x10
8 
CFU/day) fermented milk or Streptococcus thermophilus
 
(5.4 ± 1x10
8 
CFU/day) fermented milk for 7 weeks. The authors found that rats fed with both 
probiotics-fermented milk significantly decreased the incidence of aberrant crypts 
foci compared to rats fed with water and unfermented milk. Ingestion of B.
 
animalis 
and St. thermophilus fermented milk inhibited the incidence of colon aberrant crypts 
foci by 96% and 93%, respectively. In another study, Reddy and Rivenson (1993) 
demonstrated that a diet containing B. longum (2 x 10
10
 live bacterial cells/g) 
inhibited colon carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline 
(IQ). A total of 156 rats (78 female and 78 male) were fed with a control diet (high 
fat diet without containing B. longum) or experimental diet containing 0.5% 
lyophilized B. longum (2x10
10
 live bacterial cell/g) with or without IQ (125 ppm) for 
58 weeks. This randomized, placebo-controlled study found that IQ induced gut 
carcinogenesis while dietary supplementation of B. longum significantly inhibited the 
incidence of colon and small intestinal tumour in the rats.  
Several mechanisms have been proposed to explain the efficiency of 
probiotics in suppressing and preventing colon cancer. One of the potential 
mechanisms is removal of mutagens/ carcinogens via binding ability of probiotics to 
those compounds. Previous in vitro studies have reported that probiotics could 
permanently bind to dietary mutagens/ carcinogens thus inhibited the activity of the 
compounds (Bolognani et al., 1997; Lankaputhra and Shah, 1998). Another possible 
anticancer mechanism by probiotics involved the production of bioactive compounds 
(Rhee and Park, 2001) and metabolites such as short chain fatty acid (SCFA; 
Lankaputhra and Shah, 1998) which inhibited the activity of mutagens/carcinogens.  
In addition to prevention of colon cancer, probiotics are seen as an alternative 
therapy to antibiotic treatment for various infections due to their ability to improve 
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immune functions. Probiotics have been found to influence the immune functions by 
affecting components related to immunologic responses (Erickson and Hubbard, 
2000). The consumption of probiotics is capable of stimulating immune system due 
to the ability of probiotics to enhance both cytokine and secretory immunoglobulin A 
(sIgA) production. Cytokines play a significant role in stimulating the immune 
response to pathogens by activating immune cells once a pathogen is encountered. 
The chief function of sIgA is prevention of binding of foreign bacteria to epithelial 
cells and penetration of harmful microorganisms (Erickson and Hubbard, 2000). 
Thus, probiotics could protect the gastrointestinal tract from the invasion of 
pathogens and opportunistic bacteria, which would subsequently reduce the risk of 
infection. In such cases, the use of antibiotics to treat illnesses would be reduced. 
Gorbach (1996) demonstrated that Lactobacillus GG fed to adults was effective in 
treating gastrointestinal illnesses without the need for antibiotics. The preventative 
potential of probiotics in patients suffering from infectious diarrhea and upper 
respiratory tract infections has also led to the suggestion that they could be used as an 
alternative to antibiotic treatment. 
 In addition, probiotics could exert antimicrobial activity against various 
pathogenic and antibiotic-resistant strains. This antagonistic action is due to the 
production of antimicrobial substances such as bacteriocins and hydrogen peroxide. 
The use of bacteriocins is often preferred compared to antibiotics, as they are 
perceived to be more natural due to their long history of safe use in foods. Lacticin, 
the two-peptide (LtnA1 and LtnA2) lantibiotic produced by Lactococcus lactis 
subsp. lactis was reported to act against various Gram-positive pathogens, including 
methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococcus faecalis (VRE) and penicillin-resistant Pneumococcus (PRP) (Galvin 
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et al., 1999). The possible mode of action for lacticin towards Gram-positive 
pathogens involved a lipid II binding step by the LtnA1 peptide, followed by 
insertion of LtnA2 peptide into the membrane. This led to formation of pores and 
ultimately cell death (Morgan et al., 2005). Therefore, bacteriocins and other 
antimicrobial peptides produced by probiotics could act as promising therapeutic 
agents to treat various infections. 
 Probiotics could also be applied for prevention of antibiotic resistance by 
disrupting the transfer of antibiotic resistance genes. Moubareck et al. (2007) 
reported that probiotics could limit the emergence of antibiotic resistance. The 
authors evaluated the inhibitory effects of different bifidobacteria strains on the 
transfer of resistance genes among enterobacteriacea in a gnotobiotic mouse. Three 
of the five selected bifidobacteria strains successfully inhibited the transfer of 
antibiotic resistance genes and subsequently decreased the development of antibiotic-
resistant enterobacteriacea in digestive tract. Similarly, Zoppi et al. (2001) reported 
that Bifidobacterium and Lactobacillus effectively prevented antibiotic resistance. 
These probiotics were able to decrease the production of beta-lactamase in fecal flora 
after treatment with a β-lactam antibiotic. This finding suggested that probiotics 
could prevent the establishment of antibiotic resistance among intestinal microflora 
because β-lactamase is an enzyme that breaks the β-lactam ring structure 
subsequently leading to the deactivation of the β-lactam antibiotic. Production of this 
enzyme often leads to increased bacterial resistance to β-lactam-based antibiotics.  
Probiotics have also been investigated for their roles in reducing the risk of 
coronary heart disease (CHD). The risk of CHD generally increases with increasing 
levels of serum cholesterol. Past studies have demonstrated that probiotics exerted 
hypocholesterolemic effects. Liong and Shah (2005) reported that Lactobacillus 
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removed cholesterol via three possible mechanisms including assimilation of 
cholesterol, incorporation of cholesterol into cell membrane and binding of 
cholesterol to cell surface. In another study, Nguyen et al. (2007) reported that 
ingestion of 10
7 
CFU/day of L. plantarum by hypercholesterolemic mice reduced 
serum cholesterol and triglycerides levels by 7% and 10% respectively, compared to 
that of the control. Thus, considering the reduction of cholesterol level by probiotics 
in in vivo models, these beneficial bacteria could possibly reduce the risk of CHD. 
In addition, previous studies have reported promising evidences that probiotic 
fermented food exerted angiotensin I-converting enzyme (ACE)-inhibitory activity 
and antihypertensive effects due to the production of bioactive peptides (Seppo et al., 
2003). ACE is an enzyme that plays an important role in the regulation of blood 
pressure and inhibition of ACE will lead to lowering of blood pressure. Lactobacillus 
and Bifidobacterium strains have been demonstrated to possess proteolytic activity 
that could hydrolyze long oligopeptides to produce ACE-inhibitory peptides (Donkor 
et al., 2005) with antihypertensive properties. L. acidophilus, L. casei and B. lactis 
fermented yogurt have been found to contain ACE inhibitor peptides such as Val–
Pro–Pro (VPP) and Ile–Pro–Pro (IPP). L. delbrueckii subsp. bulgaricus and L. lactis 
subsp. cremoris was also reported to liberate ACE-inhibitory peptides with IC50 
ranging from 8.0 to 11.2 mg/L in milk (Gobbetti et al., 2000). This indicates that 
probiotic fermented food could be used as an alternative treatment for hypertension. 
  
2.2 Prebiotics and Synbiotics 
 Prebiotics are defined as ―a nondigestible food ingredient that beneficially 
affects the host by selectively stimulating the growth and/or activity of one or a 
limited number of bacteria in the colon‖ (Gibson and Roberfroid, 1995). Prebiotics 
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have a long history of safe use and occur naturally in food. Food components such as 
oligosaccharides and polysaccharides are of great importance to exert prebiotic 
effects. In addition, food additives and sugar alcohols such as sorbitol, xylitol and 
mannitol are also potential prebiotics which are not absorbed by the small intestines 
(Gibson and Roberfroid, 1995). Prebiotics are widely utilized in the food and 
beverage industries to improve organoleptic qualities. 
Consumption of prebiotics has been associated with various health promoting 
effects such as protection against colon cancer, enhancement of calcium absorption 
and reduction of cholesterol. The principle action of prebiotics is to modify the 
composition of intestinal microflora and thus improve the bowel health (Bruzzese et 
al., 2006). Prebiotics act as substrates to the beneficial bacteria and fermentation of 
prebiotics could produce compound with protective effects such as short chain fatty 
acids (SCFA) in the gastrointestinal tract,  such as acetate, propionate and lactate 
which subsequently reduce the pH of colon (Wong and Jenkins, 2007). The acidic 
environment exerts an antibacterial effect against other pathogens in the 
gastrointestinal tract, leading to improve gastrointestinal microbial balance and 
bowel health (Gibson and Roberfroid, 1995).  
Prebiotics ingestion and the production of SCFA have also been associated 
with improved calcium absorptions. A randomized, double-blind, crossover study 
has reported that consumption of 15 g/day of oligofructose for 9 days enhanced the 
calcium absorption of twelve male adolescent (van den Heulen et al., 1999). 
Prebiotics could increase the absorption of calcium via binding or sequestering 
calcium in the upper gastrointestinal tract. Bound or sequestered calcium on 
prebiotics would then reach the colon where it was being released from the prebiotics 
matrix and absorbed in the colon (Roberfroid, 2000). Therefore, the ingestion of 
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prebiotics would increase the absorption of calcium. The absorption of calcium has 
also been found to increase in the presence of acids in the intestines (Scholz-Ahrenz 
et al., 2001). Prebiotics are indigestible where they escape digestion of upper 
intestine and serve as the substrate for microflora population in lower intestines to 
produce SCFA. SCFA and H
+
 have been found to exchange for Ca
2+
 in the distal 
colon regions (Trinidad et al., 1996). This would then increase the concentration of 
Ca
2+
 which favour passive diffusion and consequently absorbed by the human colon 
(Roberfroid, 2000).  
In addition, insoluble prebiotics have also been demonstrated to exert 
hypocholesterolemic effects. The levels of cholesterol have been reported to reduce 
via the binding effect of prebiotics. These insoluble prebiotics could absorb 
cholesterol, fat and phospholipids in the lower intestines and subsequently excrete 
them in faeces. The insolubility of prebiotics could shorten the time of gastric transit 
and thus rapidly excrete the cholesterol and fats. Gallaher et al. (2002) proposed that 
fiber could bind with bile acids and reduce solubilisation of cholesterol leading to a 
cholesterol lowering effect. The reduction of total cholesterol regulated the receptors 
of LDL and thus increased the clearance of LDL cholesterol (Aller et al., 2004). This 
overall cholesterol lowering effect could reduce the stiffness of large arteries and 
potentially reduce blood pressure (Ferrier et al., 2002).   
In addition to cholesterol lowering effects, fibrous prebiotics has also been 
associated with the well-being of blood glucose profile and attenuation of insulin 
resistance, attributed to the insoluble fractions of prebiotics. Insoluble prebiotics are 
often extracted from native plant fibres such as cellulose, hemicelluloses, lignin and 
wheat bran. They have been found to improve postprandial glucose response and 
decrease secretion of insulin via a lowered glycemic index. The lower circulation of 
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insulin up-regulated the insulin receptors and secondary signalling molecules 
resulting in increased tissue insulin sensitivity (Robertson et al., 2003). In addition, 
other insoluble prebiotics such as high cereal fiber has also been associated with the 
reduced risk of diabetic, mainly attributed to their metabolism in the colon by 
indigenous microflora producing SCFA and their effects on hepatic insulin 
sensitivity (Schulze et al., 2007). SCFA has been suggested to improve hepatic 
insulin sensitivity (Weickert et al., 2006). Cereal fiber has a low glycemic index and 
has been studied for their roles in managing diabetes via lowering of early 
postprandial hyperglycemia and decreasing risks of post-absorptive hypoglycemia 
(Ludwig, 2002). The beneficial effects of fibrous prebiotics on blood glucose and 
lipid profile was showed in Table 2.1.  
Prebiotics such as fructans has been demonstrated to decrease the incidence 
of obesity. Past studies involving animal models mainly rats has shown promising 
evidences that ingestion of inulin-type fructans could regulate body weight via the 
promotion of endogenous glucagon-like peptide-1 (GLP-1) in the gut (Cani et al., 
2005). GLP-1 is a key hormone released from enteroendocrine-L cells in response to 
nutrient ingestion and is the key modulator of food intake by promoting satiety 
(Delzenne et al., 2007). This consequently reduces the intake of food which leads to 
a decreased in body weight and body mass index. Most of the studies involving the 
promotion of satiety by fructans via increased production of GLP-1 were performed 
in animal models and little information is available on human subjects. However, this 
remains a possible mechanism of fructans in promoting satiety. Piche et al. (2003) 
had previously demonstrated that ingestion of 6.6 g of oligofructose three times a day 
for 7 days increased the released of GLP-1 in nine subjects. Although the GLP-1 
level was not directly associated with satiety in this study, the promotion of GLP-1 in 
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human was a plausible finding of the effects of fructans in human. Additionally, it is 
interesting to note that ingestion of 16 g/day of oligofructose for 2 weeks decreased 
the total energy intake by 5% and increased satiety following breakfast and dinner in 
human subjects (Cani et al., 2006).  
 
 Table 2.1: Effects of fibrous prebiotics on blood glucose and lipid profiles 
Intervention Prebiotics 
Dose; duration 
of the study 
Experimental 
design 
Animals/ 
Subjects 
Effects Ref 
Blood 
Glucose  
Alginate 
fibre 
5.0 g sodium 
alginate 
supplement 
(algae isolate, 
75% soluble 
fibre); for two 
days 
Randomized, 
placebo-
controlled 
Seven men 
with type 2 
diabetes; 
mean age 
of 53 years 
31% reduced in 
postprandial rise of 
blood glucose (P< 
0.05) and 42% 
reduced in serum 
insulin (P< 0.02)  
Torsdottir 
et al. 
(1991)  
 Soy hulls 26 g of soy 
hulls which 
incorporated 
into 7 slices of 
bread daily; 
for 4 weeks 
Randomized, 
double-blind, 
placebo-
controlled 
Ten 
subjects (5 
male and 5 
female) 
with type 2 
diabetes; 
mean age 
of 65 ± 5.9 
years 
Significantly 
improved the 
glucose score (P< 
0.05) and the total 
area under the 
glucose curve (P< 
0.05) by 6.7% and 
7.1%, respectively 
Mahalko 
et al. 
(1984) 
Lipid 
Profile 
Pectin 75 g citrus 
pectin daily; 
for four weeks 
Randomized, 
placebo-
controlled 
Six male 
adult 
hyperchols- 
erolemic 
minipigs 
67.1% decrease in 
VLDL- cholesterol 
(P< 0.05); 41.1% 
decrease in LDL-
cholesterol (P< 
0.05); 49.4% 
decrease in total 
serum cholesterol (P 
< 0.05) 
Ahrens et 
al. (1986) 
 Fiber 
(Plantago 
ovata 
husk) 
10.5 g 
Plantago 
ovata husk 
daily; for eight 
weeks 
Randomized, 
crossover, 
placebo-
controlled, 
single-blind 
Twenty-
eight men 
with 
myocardial 
infarction 
or stable 
angina 
6.7% decrease in 
plasma 
triacylglycerol (P < 
0.02), 6.7% increase 
in HDL-cholesterol 
(P < 0.006); 10.6% 
decrease in the total 
cholesterol/HDL 
ratio (P < 0.002); 
14.2% decrease in 
LDL/HDL ratio (P< 
0.003) 
Sola‘ et 
al. (2007) 
 In addition to prebiotics, another possible approach to promote a healthier 
gastrointestinal balance is via consumption of synbiotics. Synbiotics are ingredients 
that contain a mixture of both probiotics and prebiotics to produce synergistic effects 
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on the maintenance of a desirable microbial population in the intestinal microbiota 
(Smejkal et al., 2003). The concept and beneficial effects of synbiotics has been 
widely reported in past studies. Liong and Shah (2006) has found that a synbiotic diet 
that contained L. casei, FOS, and maltodextrin significantly improved the bowel 
microbial balance and reduced serum total cholesterol. Synbiotics has also been 
suggested to reduce infection and inflammation in organ transplantation patients 
(Bengmark, 2004). In another study, Gallaher and Khil (1999) demonstrated that oral 
administration of oligofructose and bifidobacteria reduced the risk of colon cancer in 
carcinogen-treated rats. However, individual administration of bifidobacteria or 
oligofructose insignificantly reduced the aberrant crypt counts. These show that the 
use of probiotics and prebiotics in combination could provide additive health 
promoting effects.  
  
2.3 Soy 
 The consumption of soy (Glycine max)-based food has increased 
tremendously due to epidemiological and clinical evidence which showed health 
promoting effects of soy-based food. Soy provides a good source of protein as it 
contains appreciable amount of essential amino acids, low quantity of saturated fat 
without containing cholesterol. In addition to the nutritional attraction, new soy-
based products with better organoleptic properties have been produced to improve 
the acceptability of consumer towards soy-based food.  
 
2.3.1 Nutritional Profile and Health Benefits  
Consumption of soy has been associated with the prevention of hormone 
dependant diseases including osteoporosis, cardiovascular diseases and cancer. 
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Generally, these vast beneficial effects are attributed to isoflavones that occur 
abundantly in soy-based products. Isoflavones are a group of phytoestrogens which 
are structurally similar to human estradiol. Considering their structural similarity, 
isoflavones could bind to estrogen receptors and provide agonist or antagonist 
actions.  
 Previous studies have demonstrated that soy and soy isoflavones reduced the 
risk of prostate and breast cancer. Kurahashi et al. (2007) conducted a population-
based prospective study with a 5 year follow up involving 43,509 Japanese men (45 - 
74 years old) and found that isoflavones intake was associated with a decreased risk 
of localized prostate cancers. In another population based case-control study, Shu et 
al. (2001) reported that high soy intake during adolescence reduced the risk of breast 
cancer in later stage of life. The population-based study involved 1459 chinese 
women (25 - 64 years old) with newly diagnosed breast cancer and 1556 healthy 
women subjects as control.   
Soy and soy isoflavones have also been found efficient in reducing the risk of 
osteoporosis. Arjmandi et al. (1996) demonstrated that soybean diets exhibited a 
protective effect on bone.  A total of 32 female rats were ovariectomized or sham 
operated and were fed with either control diet (casein) or soy protein isolate. The 
bone density was significantly reduced after ovariectomized but the rat fed with soy 
diet showed greater vertebral and femoral bone densities compared to the 
ovariectomized rat fed with control diet. In another population-based studies, Ikeda 
et al. (2006) reported that intake of fermented soy products (natto) prevented 
postmenopausal bone loss. The study involved 944 women (20-79 years) and a 
follow up was conducted after 3 years. High consumption of fermented soy products 
increased bone mass density in postmenopausal women. 
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Soy-based food has also received considerable attention for their potential 
roles in preventing cardiovascular disease. Such protective roles of soy are attributed 
to soy protein and isoflavones that occurs naturally in soy (Sacks et al., 2006). 
Sagara et al. (2004) reported that dietary intake of soy for 5 weeks effectively 
reduced the risk of cardiovascular disease among high-risk middle-aged men. Sixty-
one men with relatively higher blood pressure and/or total cholesterol levels were 
randomly assigned to either soy-containing diet (soy powder containing at 20 g soy 
protein and 80 mg isoflavones) or placebo diet (olive oil). The authors found that 
there was a significant reduction from baseline in total cholesterol, systolic blood 
pressure and diastolic blood pressure in the soy-containing diet group, but not in the 
placebo group. In another study, Crouse III et al. (1999) conducted a double blind 
randomized parallel trial and found that naturally occurring isoflavones in soy 
protein could reduce plasma total and low density lipoprotein (LDL) cholesterol. A 
total of 156 healthy men and women were assigned to a control diet containing 25 g 
casein or 25 g soy protein diet containing 3, 27, 37 or 62 mg isoflavones. 
Administration of soy protein with 62 mg of isoflavones lowered total cholesterol by 
4% and LDL by 6% compared to that of the control.  
 
2.3.2 Antinutritive Factors        
 Soybeans like many other legumes may contain several undesirable 
antinutritive components. These components include trypsin inhibitors, phytate 
(inositol hexaphosphate), oligosaccharides and saponins. However, these 
antinutritive factors could be reduced and bioconverted into other compounds upon 
processing (Anderson and Wolf, 1995).  
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 Trypsin inhibitors occur naturally in whole soybean in an amount of 17 - 27 
mg/g of soybean. Trypsin inhibitors are considered antinutritive due to its 
interference with protein digestion. Therefore, elimination of trypsin inhibitors is 
beneficial and this could be achieved via heat processing. Being a protein, trypsin 
inhibitors are susceptible to heat and are readily inactivated and denaturated by heat 
(Anderson and Wolf, 1995). In addition, fermentation could also decrease the 
concentration of trypsin inhibitors. Hong et al. (2004) has previously reported that 
fermentation of soybean and soybean meal by Aspergillus oryzae eliminated most of 
the trypsin inhibitors in soy.  
Saponins are glycosides composed of polar sugar residues attached to a lipid 
soluble aglycones with triterpenoid structure (Messina, 1999). These components 
have been postulated to be toxic (Anderson and Wolf, 1995). However, fermentation 
could reduce the content of these components. Fermented soy products such as natto 
and miso have been reported to exhibit lower saponins content compared to 
unfermented counterparts (Anderson and Wolf, 1995). Phytic acids have been 
recognized to reduce the absorption and bioavailability of mineral in beans (Messina, 
1999). Phytic acids concentrations in soybean vary considerably and on average the 
concentration is approximately 1% - 2%. Fermentation of soybean could reduce the 
concentration of phytic acids. Egounlety and Aworh (2003) reported that 
fermentation of soybean with Rhizopus oligosporus reduced the concentration of 
phytic acids by 30%.  
Soybean oligosaccharides such as stachyose and raffinose are also regarded 
as antinutritive, as these sugars are not digested in the small intestine due to deficient 
of α-galactosidase enzyme in human intestinal. These sugars are degraded by human 
intestinal bacteria to carbon dioxide, hydrogen and methane, leading to flatulence 
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and abdominal pains. However, these sugars have also been reported to exert 
prebiotic effects (Roberfroid, 2007), and was found useful to improve the microbial 
balance in gastrointestinal tract. The antinutritive properties of soybean 
oligosacharides could be eliminated by hydrolysis with extracellular α-galactosidase 
enzyme or fermentation with microorganism that possess this enzyme such as 
lactobacilli and bifidobacteria.  
 
2.3.3 Potential Risks of Soy Consumption 
 Naturally, soy contains a reasonable amount of isoflavones which has 
chemical structure similar to that of estrogen. In recent years, estrogen used in 
hormone replacement therapy (HRT) has raised several controversies. The estrogen 
therapy has been reported to stimulate the proliferation of endometrial and mammary 
gland tissue and subsequently increase the risk of breast cancer (Wuttke et al., 2008). 
Considering the structural similarity of isoflavones and estrogens, it has been 
postulated that consumption of soy/soy isoflavones may also lead to the same side 
effects as estrogen.  
Studies on the negative effects of soy isoflavones on the mammary gland 
tissue and risks of breast cancer are limited. One of the most detailed studies was a 
cross-sectional study (<1 year) by Maskarinec and Meng (2001) which involved 514 
women (mean age: 53.9 years old) and has reported that soy intake were positively 
associated with percent mammographic densities. Mammographic densities refer to 
the distribution of fat, connective, and epithelial tissue in female breast and are 
associated with increased breast cancer risk. The study demonstrated that percent 
mammographic density of women with higher soy intake (>38.4 g/day) was 11% 
greater than that of women with lower soy intake (<6.7 g/day). However, 
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controversial finding has been reported. In another randomised placebo-controlled 
study (220 premenopausal women), women consuming 2 serving of soy/day (50 mg 
isoflavones/day) for 2 years showed no significant differences in mammographic 
densities compared to the control group (Maskarinec et al., 2008). It has been 
suggested that isoflavones do not exert an estrogenic effect similar to hormone 
replacement therapy on mammographic density and are safe for long term 
consumption.  
The safe consumption of soy by men has also been debated lately. A 
population-based prospective study (follow up from 1994 through 2005) involving 
43,509 Japanese men (ages: 45 - 74 years) has reported that consumption of soy 
isoflavones was associated with increase risk of advanced prostate cancer (Kurahashi 
et al., 2007). However, in the same study, the authors demonstrated that soy food/soy 
isoflavones intake significantly decreased the risk of localized prostate cancer. In 
another study, consumption of soy protein (107 mg isoflavones/day) has been 
reported to exert preventive effects against advanced prostate cancer in 58 men. This 
randomised study demonstrated that consumption of soy protein for 6 months 
significantly suppressed androgen receptor expression, and thus may exhibit anti-
prostate cancer potential (Hamilton-Reeves et al., 2007). Up to date, studies on 
negative effect from the consumption of soy are scarce. On the other hand, numerous 
clinical and epidemiological studis has shown promising evidences on the potential 
application of soy for the prevention of prostate cancers in men. 
 
2.4 Probiotics and Soy Products 
In the past, dairy-based products have been widely used as carriers for 
probiotics both in the developing and industrialized country. However, the 
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drawbacks of dairy-based carriers associated with cholesterol contents, lactose 
intolerance and desire for vegetarian alternative have prompted the development of 
alternative carriers for probiotics (Farnworth et al., 2007). Considering the nutritional 
content and nature of soy, soy-based products could substitute dairy-based products 
as carriers for probiotics. Soybean, a vegetarian diet is well-known as an inexpensive 
source of protein and calories for human consumption. It also contains reasonable 
amounts of bioactive ingredients without containing cholesterol or lactose (Scalabrini 
et al., 1998). Therefore, much attempt has been made to develop soy-based product 
as probiotic dietary adjuncts in recent years. 
Despite having such attractive nutritional values, consumption of soy has 
been limited mainly due to its poor organoleptic properties. Soy products often 
exhibit unpleasant beany flavour due to the presence of aldehydes such as n-hexanal 
and pentanal, produced upon hydrolysis of unsaturated acids in soymilk. One 
possible solution to overcome this limitation is via fermentation by probiotics that 
possess reductase to reduce the content of n-hexanal and pentanal in soymilk 
(Scalabrini et al., 1998). It was reported that n-hexanal was reduced from 16.5 ppb to 
4 ppb, whereas pentanal was not detected in soymilk upon fermentation with 
bifidobacteria for 24 h. Tsangalis and Shah (2004) demonstrated that 
Bifidobacterium metabolized the entire hexanal and pentanal in soymilk after 12 h of 
fermentation. According to the authors, probiotics possess complex enzyme systems, 
which responsible for catalyzing the oxidation of aldehydes into carboxylic acids. 
This indicates that probiotics could improve the organoleptic properties of soy 
products, subsequently increase the acceptability and consumption of soy products. 
Consumption of soy products fermented with probiotics has been found to be 
beneficial especially for modulation of gastrointestinal microbial balance, leading to 
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improvement of human health. Shimakawa et al. (2003) demonstrated that 
administration of B. breve strain Yakult-fermented soymilk significantly increased 
the counts of beneficial bacteria in gastrointestinal tract of 15 healthy male subjects. 
The subjects were blindly and randomly assigned to two groups each receiving either 
500 mL/day of unfermented soymilk or fermented soymilk containing 1.6 x 10
9
 
CFU/mL of B. breve for seven days. The study indicated that upon ingestion of 
fermented soymilk, total counts of Bifidobacterium in faeces were significantly 
higher than before ingestion. Thus, it appears that fermentation with probiotics is 
beneficial for development of soy products with health-promoting effects.   
 
2.4.1 Soy as Carrier for Probiotics 
In order to exert optimal probiotics effects, it is important that the numbers of 
live bacterial in food and fecal recovery of the administered bacteria are high. It has 
been suggested that probiotic organisms should be present in a food product at a 
minimum concentration of 10
6 
CFU/g (Gomes and Malcata, 1999), or the daily 
intake of approximately 10
8
 CFU to exhibit health-promoting effects. Past studies 
have reported that fermented soy-based products could fulfil both these requirements 
indicating that it serves as a potential vehicle for probiotics.  
Up to date, various studies have been conducted to verify the efficiency of 
soy-based products as a potential carrier of probiotics. Donkor et al. (2007a) reported 
that probiotics could reach the desired therapeutic level (10
6
 CFU/mL) in fermented 
soymilk due to its ability to metabolize soy oligosaccharides during fermentation. In 
addition to soymilk, other soy products were also evaluated for their efficiency to act 
as probiotic carriers. Probiotics was found to thrive well in soy yoghurt with viability 
above therapeutic levels (10
8
 CFU/mL) and remained consistent even after 28 days 
